PC
CRDF icon

Polar Capital’s Cardiff Oncology CRDF Stock Holding History

Polar Capital’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$6.71M Buy
+472,908
New +$3.12M 0.05% 199

Other funds holding CRDF

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Polar Capital's CRDF Position: Q3 2020 in Review

Polar Capital opened a new position in Cardiff Oncology (CRDF) in Q3 2020: 472,908 shares worth $6.71M. The stake represents 0.05% of the portfolio and ranks #199 among its holdings.

67 funds tracked by Wall St. Rank hold CRDF as of Q3 2020.

  • Polar Capital held 472,908 shares of Cardiff Oncology worth $6.71M as of Q3 2020.
  • Cardiff Oncology was a new Polar Capital position in Q3 2020.
  • Cardiff Oncology made up 0.05% of Polar Capital's portfolio in Q3 2020, its #199 holding.
  • 67 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.